科兴制药(688136.SH)：GB10注射液临床试验注册申请获得受

Core Viewpoint - Company received acceptance notice for clinical trial application of GB10 injection from the National Medical Products Administration, marking a significant step in the development of innovative drugs [1] Group 1: Product Development - GB10 injection is a high-concentration ophthalmic injection targeting both VEGF and Ang-2, developed by the company's wholly-owned subsidiary, Shenzhen Kexing [1] - Preclinical data indicates that GB10 injection's biological activity and animal efficacy meet international competitive standards, effectively inhibiting choroidal neovascularization in laser-induced monkey models [1] Group 2: Strategic Importance - Acceptance of the clinical trial application represents a key advancement in the company's dual-antibody research and development strategy based on its proprietary technology platform [1] - Successful future commercialization of GB10 injection could diversify the product offerings and enhance the company's market competitiveness [1]